EUVIMEDEUVIMED entdecken
Open Access

The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA

Jesse Fishman, Koo Wilson, Aleksandra Drzewiecka, Michał Pochopień, David Dingli

Journal of Comparative Effectiveness Research · 2023

DOI: 10.57264/cer-2023-0055 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Comparative Effectiveness Research, 2023. Verfasst von Jesse Fishman und 4 weiteren Autor:innen. Beteiligte Einrichtung: Apellis Pharmaceuticals, Waltham, MA 02451, USA. Hauptthemen laut MEDLINE: Hemoglobinuria, Paroxysmal. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 105 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

Paroxysmal nocturnal hemoglobinuria (PNH) is a rare blood disorder characterized by hemolytic anemia, bone marrow failure and thrombosis, and is associated with high healthcare burden. We evaluated the cost–effectiveness of pegcetacoplan, a proximal complement-3 inhibitor (C3i), compared with the C5i, eculizumab and ravulizumab, in complement treatment-naive adults with PNH, from the US healthcare payer perspective. Materials & methods: A de novo cost–effectiveness model based on a Markov cohort structure evaluated lifetime (55-year) PNH costs and outcomes. The 6-month cycles of the model reflected the follow-up period of PRINCE (NCT04085601), an open-label trial of pegcetacoplan compared with eculizumab in C5i-naive patients. Data from PRINCE informed the clinical, safety and health-related quality of life outcomes in the model.

Results

Pegcetacoplan was associated with lifetime cost savings of USD1,176,808 and USD213,062 relative to eculizumab and ravulizumab, respectively (largely attributed to reduced drug costs and blood transfusions), and additional quality-adjusted life years (QALYs) of 0.25 and 0.24.

Conclusion

In patients with PNH who are treatment-naive, the base-case cost–effectiveness analysis, scenario analysis and sensitivity analysis showed both lifetime cost savings and increased QALYs associated with pegcetacoplan compared with eculizumab or ravulizumab in the USA.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hemoglobinuria, ParoxysmalHumansAdultCost-Benefit AnalysisQuality of LifeCost-Effectiveness AnalysisPeptides, Cyclic

Stichwörter der Autor:innen

cost–effectivenesshemolytic anemiaparoxysmal nocturnal hemoglobinuriapegcetacoplanred blood cell transfusion

Substanzen

pegcetacoplanPeptides, Cyclic

Autor:innen und Institutionen

  • Apellis Pharmaceuticals, Waltham, MA 02451, USA.
  • Swedish Orphan Biovitrum AB, Stockholm, Sweden.
  • Putnam PHMR, Krakow, Poland (previously Creativ-Ceutical, Krakow, Poland during conduct of study).
  • Assignity, Krakow, Poland (previously of Creativ-Ceutical, Krakow, Poland during conduct of study).
  • Mayo Clinic, Rochester, MN 55902, USA.

Zitieren

APA

Fishman, J., Wilson, K., Drzewiecka, A., Pochopień, M., & Dingli, D. (2023). The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA. Journal of Comparative Effectiveness Research. https://doi.org/10.57264/cer-2023-0055

Vancouver

Fishman J, Wilson K, Drzewiecka A, Pochopień M, Dingli D. The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA. Journal of Comparative Effectiveness Research. 2023. doi:10.57264/cer-2023-0055

BibTeX
@article{Fishman2023,
  author = {Fishman, Jesse and Wilson, Koo and Drzewiecka, Aleksandra and Pochopień, Michał and Dingli, David},
  title = {The cost–effectiveness of pegcetacoplan in complement treatment-naïve adults with paroxysmal nocturnal hemoglobinuria in the USA},
  journal = {Journal of Comparative Effectiveness Research},
  year = {2023},
  doi = {10.57264/cer-2023-0055}
}
Kostenlos starten →